B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 5.6 HKD -2.78% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Biocytogen Pharmaceuticals Beijing Co Ltd?
Write Note

Biocytogen Pharmaceuticals Beijing Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biocytogen Pharmaceuticals Beijing Co Ltd
Net Income (Common) Peer Comparison

Comparables:
6160
603392
002252
300122
300896

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Net Income (Common)
-ÂĄ383m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
ÂĄ1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Net Income (Common)
ÂĄ1.8B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
ÂĄ6B
CAGR 3-Years
-6%
CAGR 5-Years
26%
CAGR 10-Years
48%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
ÂĄ1.9B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A

See Also

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Net Income (Common)?
Net Income (Common)
-383m CNY

Based on the financial report for Dec 31, 2023, Biocytogen Pharmaceuticals Beijing Co Ltd's Net Income (Common) amounts to -383m CNY.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
4%

Over the last year, the Net Income (Common) growth was 36%. The average annual Net Income (Common) growth rates for Biocytogen Pharmaceuticals Beijing Co Ltd have been 4% over the past three years .

Back to Top